News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Advanced Circulatory Systems Receives $1.5 Million From National Institutes of Health (NIH) for Study of Cardiac Arrest



10/14/2008 10:00:46 AM

OSHKOSH, Wis., Oct. 13 /PRNewswire/ -- Advanced Circulatory Systems, Inc. (http://www.advancedcirculatory.com) announced today that it has received an additional $1.5 million in funding from the National Institutes of Health (NIH) to continue a study testing two devices used in combination on those who experience cardiac arrest outside a hospital. Oshkosh is one of six sites included in the national study.

The study is needed because of the dismally low survival rates for cardiac arrest; the national average for surviving such a cardiac arrest that occurs outside a hospital setting is only one in twenty.

The NIH funding will be used to increase enrollment in the six-site study. The study involves the testing of the ResQPump(R) an active compression/decompression device, in combination with the ResQPOD(R), a device used to increase blood flow to the heart and brain during CPR. The ResQPOD, an impedance threshold device proven to increase circulation, has previously received clearance from the FDA and is in use at more than 1,100 customer sites in the US. The current NIH funded study is the first randomized study in the US to assess results of the ResQPump and ResQPOD used together and comparing results when CPR is performed without these devices. The ResQPump has been tested and is currently in use in Europe. Both devices are designed and manufactured by Advanced Circulatory Systems of Minneapolis, MN.

The six sites involved in the study include Minneapolis, MN; St. Paul, MN; Whatcom County, WA; Oshkosh, WI; suburban Detroit including parts of Oakland and Macomb counties, MI; and Livingston County, MI which includes the city of Ann Arbor.

The use of new technologies as well as improved CPR procedures as recommended by the American Heart Association in its latest guidelines are intended to help more people survive a cardiac arrest and with their brain function intact. Studies like the NIH funded study are believed to be among the best methods to prove how treatments can impact outcomes.

Advanced Circulatory Systems' mission is to restore life and improve the quality of life for patients suffering cardiac arrest, low blood pressure and head injury by developing new technologies to non-invasively increase circulation throughout the body, providing improved opportunity for survival and quality of life. The privately held company is based in Minneapolis, MN.

Media contact: Joanne Henry, 612-843-2142, jhenry@henryschafer.com

Advanced Circulatory Systems medical contact: Keith Lurie, M.D., Chief Medical Officer, 952-947-9590, klurie@advancedcirculatory.com

The generally cleared indication for the ResQPOD is a temporary increase in blood circulation during emergency care, hospital, clinic and home use. Studies are ongoing in the United States to evaluate the long-term benefit of the ResQPOD for indications related to patients suffering from cardiac arrest, hypotension during dialysis and severe blood loss. The references in this communication are not intended to imply specific outcome-based claims not yet cleared by the US Food and Drug Administration. Clinical study references are available upon request.

CONTACT: Joanne Henry, +1-612-843-2142, jhenry@henryschafer.com, or
William Butler, +1-612-843-2143, associate@henryschafer.com, both for
Advanced Circulatory Systems, Inc.

Web site: http://www.advancedcirculatory.com/


Read at BioSpace.com

Related News

comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES